Pain, Inflammation, and Cannabis in HIV

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

WITHDRAWN

Study Classification

OBSERVATIONAL

Study Start Date

2022-08-31

Study Completion Date

2025-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study will examine how medical cannabis use affects neuropathic pain, inflammation and adverse events in people living with HIV (PLWH) with neuropathic pain. We will study how varying ratios of THC and CBD in medical cannabis impact neuropathic pain, inflammation and adverse events.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pain Inflammation and Cannabis in HIV

NCT05554146

HIV Infections Neuropathic Pain Cannabis

COMPLETED NA

Medical Marijuana Use in HIV+ Patients Prospective Cohort Study

NCT01536899

HIV Positive Marijuana Smoking

COMPLETED

Effects of Cannabidiol and Tetrahydrocannabinol on Microbiome and Neuroinflammation in HIV

NCT05514899

HIV Cannabis THC +3 more

RECRUITING PHASE2

Effect of Cannabis and Endocannabinoids on HIV Neuropathic Pain

NCT03099005

Cannabis HIV Neuropathy Pain Syndrome

COMPLETED PHASE2

Modeling the Effects of Chronic Marijuana Use on Neuroinflammation and HIV-related Neuronal Injury

NCT04810858

Cannabis HIV Inflammation +2 more

RECRUITING NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study will examine how medical cannabis use affects neuropathic pain in PLWH with neuropathic pain. We will enroll adults with HIV who have a) neuropathic pain, b) are actively certified for medical cannabis, and c) intend to have soft gel capsule products dispensed at Vireo (medical cannabis dispensary) (including a high THC:low CBD product, an equal THC:CBD product, and a low THC:high CBD product). Over 14 weeks, data sources will include questionnaires, blood samples, urine samples; medical, pharmacy, and Prescription Monitoring Program (PMP) records. The primary independent variable will be type of medical cannabis product dispensed at dispensary, and the primary outcome will be self-reported pain.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections Neuropathic Pain Cannabis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* \>= 18 years old
* Diagnosis of HIV
* Fluency in English
* Active certification for medical cannabis
* No medical cannabis dispensed or used within the previous 30 days
* Intends to purchase soft-gel capsule medical cannabis at Vireo
* ICD-10 diagnosis code for neuropathic pain, OR
* Neuropathic pain in problem list of electronic medical record, OR
* Neuropathic pain questionnaire-short form\>0

Exclusion Criteria

* Inability to provide informed consent
* Inability to complete 14 weeks of study visits
* Medical cannabis use within 30 days prior to enrollment
* Unique pain symptoms (e.g. multiple sclerosis, rheumatoid arthritis)
* Terminal illness
* Current or prior psychotic disorder
* Street cannabis, opioid, cocaine, or benzodiazepine use in the past 30 days
* Dispensed opioids of benzodiazepines within 60 days
* Non-steroidal anti-inflammatory use within 7 days prior to enrollment
* Steroid use within the past 14 days with duration of therapy \>=21 days

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No